Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus Oral Cyclophosphamide in Indolent Lymphoma
NCT00003605Phase 2Withdrawn
- Sponsor
- Hoag Memorial Hospital Presbyterian
- Start
- May 1998
- Primary completion
- Jan 2000
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in indolent B-cell lymphoma, sponsored by Hoag Memorial Hospital Presbyterian. Planned start May 1998; status: withdrawn.
02
Drugs
rituximab
03
Conditions
indolent B-cell lymphoma
Beyond the preview
Go deeper on NCT00003605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003605.